近日,在Cancer期刊上,研究人员在线发表了题为“Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China”的评论文章。 作者通过国内外研究的比较,重点介绍了在国内开展的基于CAR-T细胞、CAR-NK细胞和CAR-巨噬细胞...
And which tumor specific anti-tumor cells are mainly used for the treatment of HCC by CAR-T cell therapy? Dr. Ho: Well, that's a really good question. We do not know exactly how CAR-T cell treatment in liver cancer is re...
3.Gregory P Botta.Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells[J].J Immunother Cancer. 2024 Feb 5;12(2):e007927. doi: 10.1136/jitc-2023-007927. 4.Kohei Shitara.Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin...
[2]Gustafson MP, Ligon JA, Bersenev A, et al. Emerging frontiers in immuno- and gene therapy for cancer. Cytotherapy. 2023 Jan;25(1):20-32. doi: 10.1016/j.jcyt.2022.10.002. Epub 2022 Oct 22. PMID: 36280438; PMCID: PMC9790040. [3]Taylor MR, Steineck A, Lahijani S, et al. Bi...
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in soli...
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy of Cancer. Journal for ImmunoTherapy of Cancer; 2017;5:1–13 4. Sanchez-Paulete AR, Mateus-Tique J, Mollaoglu G, et al. Targeting macrophages with CAR T cells delays solid tumor progression ...
嵌合抗原受体(CAR)T细胞疗法(后简称“CAR-T细胞疗法”)指通过对人体T细胞进行工程化改造,使T细胞能够特异性靶向清除肿瘤细胞,从而达到精准治疗癌症的目的。过去的十几年里,CAR-T细胞疗法改变了恶性血液肿瘤…
可以「治愈」白血病等恶性血液系统肿瘤的抗癌药 CAR-T 治疗产品,最近却被质疑有引发 T 细胞淋巴瘤(T-cell Malignancy)的风险? 前天,FDA 发布公告:部分 CAR-T 治疗产品可能诱发 T 细胞淋巴瘤的「严重风险」,正在对当前已上市的 6 款 CAR-T 治疗产品进行调查[1]。其中,有 3 款已经在国内获批上市。
01、CAR-T疗法:精准打击多款血液肿瘤 CAR-T细胞(嵌合抗原受体T细胞)疗法是一种以T细胞介导的CAR为基础的细胞免疫疗法,通过插入一段编码嵌合抗原受体(CAR)的DNA片段,对患者自身的T细胞进行基因重新编程,将其改造成自带“导航头”的武器,以靶向特定的肿瘤细胞,产生即时和长期的抗癌影响,为复发或难治性恶性肿瘤,特别是...
目前将细胞毒性T细胞重新导向肿瘤抗原的方法有两种分别是CAR-T和TCEs,前者和后者都已经在液体瘤中证明其良好的疗效,而在临床方面CAR-T更受青睐。 在实体瘤中,尽管越来越多的实体瘤临床已经展开,但因为实体瘤微环境(TME)的各方面特殊影响,因此急需要理清TCEs面临的挑战和解决策略。